Quality Improvement for Institutions
www.cvquality.acc.org

Cardiovascular Quality and Research News

ACC CV Quality SmartBrief

The ACC CV Quality SmartBrief eNewsletter is a free, twice-weekly briefing for health care stakeholders interested in quality care. Learn more about the ACC CV Quality SmartBrief and subscribe.

  • Social prescribing gains traction for holistic care

    Social prescribing is becoming more popular globally as a complementary approach to traditional medical treatments, focusing on activities such as exercise, art, and volunteering to improve physical and mental health. About 30 countries, including the US, have implemented social prescribing programs, with studies showing it not only enhances health but also reduces health care costs, as shown by decreased emergency department visits and hospitalizations. National Public Radio (7/14) Learn More

  • Catheter ablation, lifestyle change both have roles for AFib

    The PRAGUE-25 study found that catheter ablation was more effective than a combination of lifestyle changes and antiarrhythmic medications in preventing atrial tachyarrhythmia recurrences in individuals with atrial fibrillation and obesity. However, lifestyle changes such as weight loss and increased exercise led to greater decreases in weight and HbA1c. "The referral to catheter ablation in this population should not be delayed until the patient loses weight," researchers wrote. "Nonetheless, patients with obesity should not be discouraged from losing weight, because several other significant benefits are associated with weight reduction." Related findings were published in JACC and presented at ACC.25. TCTMD (7/15) Learn More

  • Baxdrostat successful in phase 3 hypertension trial

    AstraZeneca's aldosterone synthase inhibitor baxdrostat achieved its primary endpoint in the phase III BaxHTN trial for uncontrolled or treatment-resistant hypertension, significantly reducing mean seated systolic blood pressure when added to existing treatments. The drug, acquired through the $1.3 billion purchase of CinCor Pharma, showed mixed results in earlier studies but is expected to be used in combination with Farxiga for chronic kidney disease and heart failure. PharmaPhorum (UK) (7/14) Learn More

  • Alert system, usual care similarly improve BP med adherence

    Medscape (7/10) Learn More

  • Some UTI antibiotics may raise infant malformation risk

    MedPage Today (free registration) (7/11) Learn More

  • What patients need to know about protecting against measles

    Cardiology Advisor (7/3) Learn More

  • Power Up Your CV Program With ACC Accreditation

    ACC Accreditation Services is offering a special summer promotion: 15% off your first accreditation payment. Designed to help multidisciplinary teams identify gaps in care and accelerate improvements in quality, ACC Accreditation programs cover the full spectrum of cardiovascular care. Learn more and contact accreditationinfo@acc.org to secure this special offer. Learn More

Temp Styles

American College of Cardiology: 2400 N St. NW, Washington DC 20006